

**Human Recombinant Gastric Inhibitory Polypeptide Receptor Stable Cell Line****Cat. No. M00486****Version 05282014**

|     |                                    |   |
|-----|------------------------------------|---|
| I   | Introduction .....                 | 1 |
| II  | Background.....                    | 1 |
| III | Representative Data.....           | 2 |
| IV  | Thawing and Subculturing.....      | 2 |
| V   | References .....                   | 3 |
|     | Limited Use License Agreement..... | 4 |

**I. INTRODUCTION**

Catalog Number: M00486

Cell Line Name: CHO-K1/GIP/Gα15

Gene Synonyms: GIPR; MGC126722

Expressed Gene: Genbank Accession Number NM\_000164; no expressed tags

Host Cell: CHO-K1/Gα15

Quantity: Two vials of frozen cells ( $3 \times 10^6$  per vial)

Stability: 16 passages

Application: Functional assay for GIP receptor

Freeze Medium: 45% culture medium, 45% FBS, 10% DMSO

Complete Growth Medium: Ham's F12, 10% FBS

Culture Medium: Ham's F12, 10% FBS, 200 µg/ml Zeocin, 100 µg/ml Hygromycin B

Mycoplasma Status: Negative

Storage: Liquid nitrogen immediately upon delivery

**II. BACKGROUND**


Gastric inhibitory polypeptide receptor GIPR is a Gs-coupled GPCR which is expressed in the pancreas, stomach, small intestine, adipose tissue, adrenal cortex, pituitary, heart, testis, endothelial cells, bone, trachea, spleen, thymus, lung, kidney, thyroid, and several regions in the CNS. Its ligand GIP is secreted after meal ingestion has been shown to stimulate bone formation resulting in lower occurrences of osteoporosis. GIPR may have therapeutic potential in the treatment of type 2 diabetes and obesity.

§: GenScript employs a PCR-based method to test the mycoplasma. The test covers 11 of the most common strains of mycoplasma, (covering approximately 95% of *M. fermentans*, *M. hyorhinis*, *M. arginini*, *M. orale*, *M. salivarium*, *M. hominis*, *M. pulmonis*, *M. arthritidis*, *M. neurolyticum*, *M. hyopneumoniae* and *M. capricolum*) and one species *Ureaplasma* (*U. urealyticum*), with sufficient sensitivity and specificity.

**860 Centennial Ave., Piscataway, NJ 08854, USA**Toll-Free: 1-877-436-7274 Tel: 1-732-885-9188 Fax: 1-732-210-0262 Email: [product@genscript.com](mailto:product@genscript.com) Web: [www.genscript.com](http://www.genscript.com)

### III. REPRESENTATIVE DATA

Concentration-dependent stimulation of intracellular calcium mobilization by GIP in CHO-K1/GIP/Gα15 and CHO-K1/Gα15 cells



**Figure 1.** GIP-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/GIP/Gα15 and CHO-K1/Gα15 cells. The cells were loaded with Calcium-4 prior to stimulation with a GIP receptor agonist, GIP. The intracellular calcium change was measured by FlexStation. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (10-fold dilution) of GIP (Mean ± SD, n = 2). The EC<sub>50</sub> of GIP on GIPR co-expressing with Gα15 in CHO-K1 cells was 4.9 nM.

#### Notes:

- EC<sub>50</sub> value is calculated with four parameter logistic equation:  

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{-(\text{LogEC}_{50} - X) \cdot \text{HillSlope}})$$

X is the logarithm of concentration. Y is the response  
Y is RFU and starts at Bottom and goes to Top with a sigmoid shape.
- Signal to background Ratio (S/B) = Top/Bottom

### IV. THAWING AND SUBCULTURING

#### Thawing Protocol

- Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
- Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
- Pellet cells by centrifugation at 200 x g force for 5 min, and remove the medium.
- Resuspend the cells in complete growth medium.
- Transfer the cell suspension to a 10 cm dish with 10 ml of complete growth medium.
- Grow the cells in incubator with 37°C, 5 %CO<sub>2</sub>.
- In the following day, replace the cells with fresh medium contains antibiotic.

860 Centennial Ave., Piscataway, NJ 08854, USA

Toll-Free: 1-877-436-7274 Tel: 1-732-885-9188 Fax: 1-732-210-0262 Email: [product@genscript.com](mailto:product@genscript.com) Web: [www.genscript.com](http://www.genscript.com)

**Sub-culturing Protocol**

1. Remove the culture medium from cells.
2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 ml of 0.05% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25300) solution into 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).  
Note: To avoid cells clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells detach. If cells are difficult to detach, please place the dish in 37°C incubator for ~2 min.
4. Add 6.0 to 8.0 ml of complete growth medium into dish and aspirate cells by gently pipetting.
5. Centrifuge the cells at 200 x g force for 5min, and remove the medium.
6. Resuspend the cells in culture medium and add the cells suspension to new culture dish.
7. Grow the cells in incubator with 37°C, 5 %CO<sub>2</sub>.

Subcultivation Ratio: 1:3 to 1:8 weekly.

Medium Renewal: Every 2 to 3 days

**V. REFERENCES**

1. Irwin *et al.* (2009) Therapeutic potential for GIP receptor agonists and antagonists. *Best Pract Res Clin Endocrinol Metab* 23:499-512.
2. Yamada *et al.* (1995) Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA. *Genomics* 29:773-776.
3. Tsukiyama K *et al.* (2006) Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. *Mol Endocrinol.* 2006 Jul;20(7):1644-51.

**GenScript USA Inc,**

860 Centennial Ave.

Piscataway, NJ 08854

Toll-Free: 1-877-436-7274

Tel: 1-732-885-9188, Fax: 1-732-210-0262

Email: [product@genscript.com](mailto:product@genscript.com)

Web: <http://www.genscript.com>

**For Research Use Only.**

---

**860 Centennial Ave., Piscataway, NJ 08854, USA**

Toll-Free: 1-877-436-7274 Tel: 1-732-885-9188 Fax: 1-732-210-0262 Email: [product@genscript.com](mailto:product@genscript.com) Web: [www.genscript.com](http://www.genscript.com)

## Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- 1) The products are not transferable and will be used at the site where they were purchased. Transfer to another site owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products or its components are used for research purposes only.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for purposes other than research, contact Marketing Department, GenScript USA Inc., 860 Centennial Avenue, Piscataway, New Jersey 08854, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: [marketing@genscript.com](mailto:marketing@genscript.com).